Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News.
Danish pharmaceutical company Lundbeck made an undisclosed milestone payment to biotech Ossianix Inc., after experiments showed that shark antibodies effectively shuttled potential drugs across the blood-brain barrier in mice. The 2 companies established a research collaboration in 2014, focusing on technology development and the delivery of antibody-based therapies across the blood-brain barrier. Get the full […]